

## **ObsEva SA appoints Ben T.G. Tan as VP Commercial & Business Development**

September 10, 2014 3:49 PM ET

**Geneva, Switzerland, 10 September 2014 – ObsEva**, a Swiss-based, specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine, announced today the appointment of Ben T.G. Tan as Vice President Commercial & Business Development.

Ben brings to ObsEva over 25 years of business development, licensing and strategic marketing experience in clinical-stage biotechnology and pharmaceutical companies.

*"I am delighted that Ben is joining ObsEva, as his experience will be invaluable for further expanding and optimising ObsEva's product pipeline to address unmet medical needs and to create the highest value for all our stakeholders "* stated Ernest Loumaye, CEO and Co-Founder of ObsEva.

Ben joins ObsEva from Evolva SA, where he successfully divested its lead Phase 2 asset as part of Evolva's strategic shift away from pharmaceutical development and towards ingredients for health, wellness and nutrition. As Head of Business Development & Licensing at Speedel AG (2001-2008), Ben in-licensed preclinical and clinical assets and contributed to Speedel's IPO in September 2005. After Speedel's acquisition by Novartis Pharma AG for CHF 1 billion in 2008, he joined Novartis as Global Program Strategic Marketing Director and led the commercialisation activities for an antiplatelet drug. Prior to Speedel, Ben was Head of Global Licensing at Organon NV, a leader in Women's Health Care.

Ben began his pharmaceutical industry career at Roche Netherlands as a sales representative for hospital products and progressed to become Head of Medical Marketing, in which role he successfully launched Neupogen (filgrastim) in a co-promotion with Amgen Europe, before moving to Roche HQ in Basel as Global Business Leader for various Phase 3 assets in co-development with Sigma-Tau and Genentech.

Ben holds an MS (cum laude) in Medical Biology from the Vrije Universiteit Amsterdam.

– ends –

### **About ObsEva**

ObsEva SA is a Swiss-based, specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in various positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.

ObsEva's founding assets are innovative products at early stages of clinical development addressing preterm labor and infertility treatment as well as additional indications in reproductive medicine.

For more information, please visit [www.obseva.com](http://www.obseva.com).

For further information, please contact ObsEva CEO Office:

Delphine Renaud

Tel: +41 22 552 1550

Email: [delphine.renaud@obseva.ch](mailto:delphine.renaud@obseva.ch)